Compare CCTG & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCTG | ENVB |
|---|---|---|
| Founded | 1993 | 1994 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.9M | 8.1M |
| IPO Year | 2022 | 2000 |
| Metric | CCTG | ENVB |
|---|---|---|
| Price | $0.61 | $1.46 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 97.5K | ★ 99.0K |
| Earning Date | 12-23-2025 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,914,675.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.08 | $0.56 |
| 52 Week High | $5.64 | $13.25 |
| Indicator | CCTG | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 51.87 |
| Support Level | $0.38 | $1.17 |
| Resistance Level | $0.65 | $1.53 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 15.47 | 79.99 |
CCSC Technology International Holdings Ltd, through its direct wholly-owned subsidiaries, is principally engaged in the manufacturing and sale of interconnect products, including connectors, cables and wire harnesses. The company produces both original equipment manufacturer (OEM) and original design manufacturer (ODM) interconnect products for manufacturing companies that produce end products, as well as for electronic manufacturing services (EMS) companies. The majority of the company's revenue is derived from the sale of Cable and wire harnesses, and Connectors. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas, Asia, and Others.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.